Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Frontera London

- PMLiVE

Novo Nordisk’s insulin icodec shows promise as once-weekly type 2 diabetes treatment

Currently, the basal insulin products with the longest duration are injected once daily

- PMLiVE

The Holy Grail of healthcare pricing

By Rohit Khanna

- PMLiVE

Incyte to acquire Villaris Therapeutics to expand inflammation and autoimmunity portfolio

Auremolimab, which has proven efficacy for vitiligo, is included in the deal

- PMLiVE

Biogen and Denali dose first patients with LRRK2 inhibitor in Parkinson’s disease study

Mutations in the LRRK2 gene are one of the most common causes of familial Parkinson’s disease

KOL Insights in a Digital World

Presented at Evidence Life Science’s Medical Affairs KOL Engagement & Insights Conference, November 17, 2021 with Christina L. Hoffman, MS, Global Head, Medscape Medical Affairs

Medscape Medical Affairs

- PMLiVE

Dexcom launches next-generation continuous glucose monitor for diabetes patients

The monitor allows patients to track their glucose levels without using a finger prick test

- PMLiVE

Report: Reinventing product and portfolio value for the biopharmaceutical industry

Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...

Avalere Health

- PMLiVE

Medscape Medical Affairs

Medscape's New Unit to Support Pharmaceutical Medical Affairs

Medscape Medical Affairs

- PMLiVE

How AI is finally helping rare diseases gain more than just attention

By Neil Thompson

- PMLiVE

WHO unveils new initiative to halt spread of invasive malaria vector in Africa

Anopheles stephensi thrives in urban settings, where 40% of the population in Africa live

- PMLiVE

NHS England launches lung cancer awareness drive in country’s cancer hotspots

Only 57% of those surveyed recognised a persistent cough as a symptom of lung cancer

- PMLiVE

InflaRx seeks FDA authorisation for vilobelimab for critically ill COVID-19 patients

A phase 3 study showed that the antibody reduced the all-cause mortality rate after 28 days

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links